Uptravi (selexipag)

Manufacturer:

Johnson & Johnson

Route of Administration:

Oral

Site of Care:

Outpatient

Website:

Manufacturer Website

phone:

Enrollment Forms:

Patient Support Form

VA Enrollment Form

Approved Indication:

treatment of pulmonary arterial hypertension (PAH, WHO group 1) to delay disease progression and reduce the risk of hospitalization for PAH

Conditions:

Pulmonary Arterial Hypertension